Related Experiment Video
Updated: Feb 8, 2026
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Tumor angiogenesis and anti-angiogenic gene therapy for cancer
Tinglu Li1,2,3, Guangbo Kang1,2,3, Tingyue Wang1,2,3
1Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, P.R. China.
Abstract:
When Folkman first suggested a theory about the association between angiogenesis and tumor growth in 1971, the hypothesis of targeting angiogenesis to treat cancer was formed. Since then, various studies conducted across the world have additionally confirmed the theory of Folkman, and numerous efforts have been made to explore the possibilities of curing cancer by targeting angiogenesis. Among them, anti-angiogenic gene therapy has received attention due to its apparent advantages. Although specific problems remain prior to cancer being fully curable using anti-angiogenic gene therapy, several methods have been explored, and progress has been made in pre-clinical and clinical settings over previous decades. The present review aimed to provide up-to-date information concerning tumor angiogenesis and gene delivery systems in anti-angiogenic gene therapy, with a focus on recent developments in the study and application of the most commonly studied and newly identified anti-angiogenic candidates for anti-angiogenesis gene therapy, including interleukin-12, angiostatin, endostatin, tumstatin, anti-angiogenic metargidin peptide and endoglin silencing.
Insights
Targeting tumor angiogenesis with gene therapy shows promise for cancer treatment. This review covers anti-angiogenic gene therapy, focusing on key candidates and delivery systems for improved cancer cure strategies.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- The link between tumor angiogenesis and cancer growth was proposed in 1971.
- Targeting angiogenesis is a validated strategy for cancer therapy.
- Anti-angiogenic gene therapy offers potential advantages for cancer treatment.
Purpose of the Study:
- To provide an updated review of tumor angiogenesis.
- To discuss gene delivery systems for anti-angiogenic gene therapy.
- To highlight recent advancements in anti-angiogenic gene therapy candidates.
Main Methods:
- Review of scientific literature on tumor angiogenesis and gene therapy.
- Focus on pre-clinical and clinical studies.
- Analysis of commonly studied and novel anti-angiogenic agents.
Main Results:
- Confirmation of angiogenesis's role in tumor growth.
- Exploration of various anti-angiogenic gene therapy methods.
- Progress in pre-clinical and clinical applications.
Conclusions:
- Anti-angiogenic gene therapy is a developing field with significant potential.
- Further research is needed to overcome existing challenges for complete cancer cure.
- Key anti-angiogenic candidates include interleukin-12, angiostatin, endostatin, tumstatin, and endoglin silencing.
Related Concept Videos
00:59Gene Therapy
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Mechanism of Angiogenesis